Viatris

Argus Upgrades Viatris to Buy with $15 Target on Share Buybacks and Debt Reduction Confidence

Argus Research Upgrades Viatris Buy Rating to $15

Viatris shares rise 5.09% after-hours as analysts upgrade ratings and ETF buys shares, citing regulatory progress and affordable medicine focus.

Viatris shares rise 5.01% intraday as Burney ETF buys 222K shares and analysts upgrade to Buy.

Viatris Price Target Boosted to $16 Amid Affordable Medicines Theme

Catalyst<ul> <li>A recent Bullish Engulfing pattern on January 8 suggests a potential upward momentum for VTRS.</li> <li>Fundamental factors such as strong cash reserves relative to market value and efficient asset turnover are supporting VTRS's financial health.</li> <li>Analyst ratings show a consistent Buy recommendation, indicating institutional optimism about VTRS's outlook.</li></ul>Risk<ul> <li>Technical indicators remain mixed with signals like MACD Death Cross and RSI Overbought suggesting uncertainty in directional movement.</li> <li>Fund flows show a split in investor behavior, with negative trends among medium and large orders potentially signaling caution.</li></ul>

Key Factors

Argus upgrades VTRS to Buy with a $15 price target citing share buybacks and debt reduction strategies.

VTRS News